Jason A Zell
Overview
Explore the profile of Jason A Zell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
1949
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Monson S, Chen P, Gangi A, Waters K, Billet S, Hendifar A, et al.
Transl Gastroenterol Hepatol
. 2025 Feb;
10:11.
PMID: 39944579
Background And Objective: Globally, colorectal cancer (CRC) is the third most commonly diagnosed cancer. CRC is known to arise from precancerous polyps known as adenomas. Although there are genetic syndromes...
2.
Clair K, Wolford J, Zell J, Bristow R
Hematol Oncol Clin North Am
. 2024 Nov;
39(1):67-87.
PMID: 39510678
This article addresses the role of surgery in the management of gynecologic cancers with liver metastases. The authors review the short-term and long-term outcomes of aggressive resection through retrospective and...
3.
Oviedo P, Burns S, Chen W, Mandl H, Rosso C, Radgoudarzi N, et al.
J Surg Oncol
. 2024 Jun;
130(2):276-283.
PMID: 38894577
Background And Objectives: The SARS-COVID-19 pandemic significantly limited healthcare access. We sought to evaluate whether California's lockdown in March 2020 affected staging and time to treatment of pancreatic ductal adenocarcinoma...
4.
Rosso C, Marciano N, Nathan D, Chen W, McLaren C, Osann K, et al.
J Natl Compr Canc Netw
. 2024 Jun;
22(5):299-305.
PMID: 38889755
Background: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year overall survival rate of 10%. In November 2018, NCCN recommended that all patients with PDAC receive genetic counseling...
5.
Jafari M, Mesiti A, Brouwer J, McKinney C, Wenzel L, Pigazzi A, et al.
Cancer Treat Res Commun
. 2024 Mar;
39:100798.
PMID: 38447475
Introduction: We have shown in a Phase I trial that immediate adjuvant chemotherapy (IAC) during surgical resection and immediately postoperative is safe and feasible in patients with colon cancer (CC)....
6.
Sepassi A, Li M, Zell J, Chan A, Saunders I, Mukamel D
Oncologist
. 2024 Jan;
29(4):e431-e446.
PMID: 38243853
Background: Rural residents have a higher prevalence of colorectal cancer (CRC) mortality compared to urban individuals. Policies have been aimed at improving access to CRC screening to reduce these outcomes....
7.
Dayyani F, Balangue J, Valerin J, Keating M, Zell J, Taylor T, et al.
Clin Colorectal Cancer
. 2023 Dec;
23(1):67-72.
PMID: 38103947
Introduction: This study determined the safety and recommended phase 2 dose (RP2D) of the multikinase inhibitor cabozantinib in combination with trifluridine/tipiracil (FTD/TPI) in refractory metastatic colorectal carcinoma (mCRC). Patients And...
8.
Ubbaonu C, Chang J, Ziogas A, Mehta R, Kansal K, Zell J
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067290
Background: The National Comprehensive Cancer Network guidelines were designed to improve patient outcomes. Here, we examine factors that may contribute to outcomes and guideline adherence in patients with triple-negative breast...
9.
Kennecke H, Auer R, Cho M, Dasari N, Davies-Venn C, Eng C, et al.
J Natl Cancer Inst
. 2023 Aug;
115(12):1457-1464.
PMID: 37535679
The optimal management of locally advanced rectal cancer is rapidly evolving. The National Cancer Institute Rectal-Anal Task Force convened an expert panel to develop consensus on the design of future...
10.
Zukin E, Culver J, Liu Y, Yang Y, Ricker C, Hodan R, et al.
Genet Med
. 2023 Apr;
25(7):100837.
PMID: 37057674
Purpose: The aim of this study was to describe the clinical impact of commercial laboratories issuing conflicting classifications of genetic variants. Methods: Results from 2000 patients undergoing a multigene hereditary...